ASMIK MKRTYCHYAN: Open Payments
NPI 1295024743 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$581 in 32 payments from 12 companies in 2025. Trend: 2023 $445 · 2024 $761 · 2025 $581
Food & beverage: $581
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $144 |
| AstraZeneca Pharmaceuticals LP | 7 | $122 |
| Novo Nordisk Inc | 4 | $72 |
| ABBVIE INC. | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| PFIZER INC. | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Exact Sciences Corporation | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $16 |
Products named: CAPLYTA, AIRSUPRA, Rybelsus, VRAYLAR, REXULTI, Auvelity, Cologuard Collection Kit, JARDIANCE.
Industry payments across MI — which companies pay providers there.
